ScienceDex / Researcher record
Mahan, Lawrence
- Madeleine Pharmaceuticals, Inc. (no department on record)
From the FY2022 NIH awards this investigator leads as contact PI. The department is the award's.
NIH Funding · FY2022
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2016 | $1,996,767 | 1 | #2,753 |
| 2021 | $1,044,010 | 1 | #8,774 |
| 2022 | $1 | 1 | #49,399 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY20161 record
- FY20211 record
- FY2022 · selected1 record
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2016 through FY2022Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2022 award records by amount
NIH award records listing Mahan, Lawrence as a PI. Multi-PI records show the full award amount for context.
- 5R44HL131086-04R44Contact PIA Phase 2a Clinical Study of a Cardiac Hormone for the Outpatient Treatment of Worsening Heart Failure$1award amount
Award organization
Organizations that administered FY2022 awards listing Mahan, Lawrence as a PI.
FY2022 award administered by Madeleine Pharmaceuticals, Inc. ().
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2016First NIH AwardMadeleine Pharmaceuticals, Inc.
- 2016$500K Cumulative Funding
- 2016$1M Cumulative Funding
- 2016Entered Top 50% NationallyRanked #2753
- 2016Entered Top 25% NationallyRanked #2753
- 2021$2M Cumulative Funding